Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

The study, published in Nature, utilized CRISPR-Cas9 gene-editing technology ... more informed decisions regarding cancer screening, preventive measures and treatment strategies.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

will be investigating the method’s safety and tolerability in patients with non-small cell lung cancer (NSCLC) whose disease has progressed after previous standard treatment. The CRISPR-Cas9 ...

As the company leverages its proprietary CRISPR/Cas9 platform to address serious ... could revolutionize cancer treatment by providing off-the-shelf cellular therapies. Success in this area ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Bristol Myers Squibb's FDA nod for Breyanzi (liso-cel) in relapsed/refractory CLL/SLL boosts its CAR T-cell portfolio, ...